InvestorsHub Logo
Followers 3
Posts 117
Boards Moderated 0
Alias Born 02/16/2015

Re: None

Monday, 10/22/2018 8:20:10 PM

Monday, October 22, 2018 8:20:10 PM

Post# of 1518
Based on gross revenues of approximately $250 million in 2019, we estimate that Opiant would receive approximately $34.3 million in royalty and milestone payments (and result in net revenues to Emergent of approximately $215 million). This assumes that sales of NARCAN® Nasal Spray do not exceed $200 million in 2018, as Opiant is owed a $15 million milestone at that threshold.

https://finance.yahoo.com/news/opnt-adapt-pharma-acquired-650-190000844.html